Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,720
+350 (3.38%)
At close: Aug 24, 2026

Ahn-Gook Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
16,2687,48116,8451,2906,8753,939
Depreciation & Amortization
8,9528,7787,6985,0234,9304,507
Loss (Gain) From Sale of Assets
-25.97-46.41-13,216-17.13-28.25-138.65
Asset Writedown & Restructuring Costs
2.752.75219.98-37.78-
Loss (Gain) From Sale of Investments
-1,409-989.18-229.34-920.69889.36-2,033
Loss (Gain) on Equity Investments
293.17579.82-1,3521,6411,645-2,613
Provision & Write-off of Bad Debts
-266.3976.64-83.27757.97129.7171.68
Other Operating Activities
3,382-269.038,1654,7475,4788,724
Change in Accounts Receivable
29,47030,2263,541-7,972-11,980-10,171
Change in Inventory
-9,664-8,710-10,008-12,861-4,497-3,969
Change in Accounts Payable
2,2363,505-4,9312,5692,5281,090
Change in Other Net Operating Assets
1,5555,049-1,7354,415-4,2191,964
Operating Cash Flow
50,79445,6834,914-1,3281,7881,472
Operating Cash Flow Growth
145.21%829.63%--21.49%-86.84%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-9,150-8,465-75,887-5,474-2,931-4,035
Sale of Property, Plant & Equipment
6611,83311,20115.542.09
Cash Acquisitions
-2,224-2,224----
Sale (Purchase) of Intangibles
-183.4-131.34-395.05-708.77-735.39-1,028
Investment in Securities
-4,336-1,584-10,93812,1679,9604,931
Other Investing Activities
-0-00-062.75
Investing Cash Flow
-15,887-12,398-75,38617,1866,4313,118

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--60,00010,000--
Long-Term Debt Repaid
--5,244-301.93-12,593-662.99-889.69
Net Debt Issued (Repaid)
-264.25-5,24459,698-2,593-662.99-889.69
Repurchase of Common Stock
-----554-435.14
Dividends Paid
-5,001-5,001-2,500-2,500-2,511-2,521
Other Financing Activities
---0---
Financing Cash Flow
-5,265-10,24457,198-5,093-3,728-3,846

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
120.7263.62127.648.0877.69136.61
Net Cash Flow
29,76223,104-13,14710,7724,569881.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
41,64337,218-70,972-6,802-1,143-2,563
Free Cash Flow Growth
373.83%-----
Free Cash Flow Margin
12.62%12.13%-26.18%-2.91%-0.56%-1.57%
Free Cash Flow Per Share
3665.443274.68-6243.89-598.47-100.42-223.77
Levered Free Cash Flow
43,60737,633-82,4724,4911,732-988.07
Unlevered Free Cash Flow
45,25939,355-80,5954,5811,832-915.05

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,6612,8072,665976.99662.47121.11
Cash Income Tax Paid
4,0625,461652.732,921713.85101.29
Change in Working Capital
23,59730,070-13,134-13,849-18,168-11,086